Fig. 2.
Patient flow diagram. In the aliskiren/HCTZ group, AEs (n = 6) were deep vein thrombosis, fatigue, hypoesthesia, palpitation, blurred vision, and dehydration/pollakiuria (n = 1, respectively). In the ramipril group, AEs (n = 3) were peripheral edema, increased blood creatinine phosphokinase and convulsion (n = 1/0.5%, respectively).
